Eloralintide
Also known as: LY3841136
Status
In trials. Not approved. In phase 3 development with Eli Lilly.
What it is
A weekly amylin receptor agonist from Lilly, in phase 3 for obesity.
What published research measured
A selective amylin receptor agonist rather than a dual agent. The ENLIGHTEN phase 3 program began recruiting in 2026, including a study of 1,980 adults with obesity or overweight without type 2 diabetes. It is being developed both as monotherapy and as a partner for tirzepatide, on the same reasoning behind every amylin program: the receptor is separate from the incretin receptors, so the effects may add without the gastrointestinal burden compounding.
Source
Bhattachar S et al. 2026 — Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept · Billings LK et al. 2025 — Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, doubl… · Briere DA et al. 2025 — Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical pr…
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.